Boston, MA | December, 8-10, 2026

www.oligonucleotide-based-therapeutics.com

SAVE $1000 BY REGISTERING BEFORE FRIDAY, SEPTEMBER 18

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

2nd Annual

Oligonucleotide-based Therapeutics Summit

Innovating Precision Delivery & Capturing Novel Chemistry

Maximizing the Affinity, Specificity, & Efficacy of Oligonucleotide Therapeutics through Smarter Chemistry & Tissue- & Cell-Specific Delivery to Translate Innovation into Clinical Success

Expert Speakers Include:

Jiabao Zhang
Senior Scientist
Biogen

Jacek Ostrowski
Senior Director, Protein Science
Avidity Bioscience

Paul Peng
Vice President, Head of CMC
City Therapeutics

Alfica Sehgal
Chief Scientific Officer
Judo Therapeutics

Julia Alterman
Assistant Professor
UMass Chan Medical School

Steven Dowdy
Professor
UCSD Medical School

"The meeting was great for networking; the panelists and presenters were all high caliber and the ensuing discussions very informative"

Apellis Pharmaceuticals

+1 617 455 4188 info@hansonwade.com

www.oligonucleotide-based-therapeutics.com

hansonwade

Your Exclusive Opportunity to Network & Propel Innovation in Oligonucleotide Development

2nd Annual Oligonucleotide-based Therapeutics Summit

December, 8-10, 2026 | Boston, MA

With continued clinical validation across oligonucleotide-based therapies and rapid innovation in delivery technologies and innovative chemistries, oligonucleotides are moving decisively from niche applications into broader landscapes to harness the full potential of oligonucleotides.

The **2nd Oligonucleotide-Based Therapeutics Summit** goes beyond proving the promise of oligo-based drugs, carefully designed for oligo scientists actively tackling the most pressing challenges: **achieving tissue-** and **cell-specific delivery** beyond the liver and improving the therapeutic index through smarter chemistry. As pipelines expand and modalities diversify, the need for **peer-to-peer networking** and **deep dive discussions** to evaluate and brainstorm innovation to overcome the challenges is crucial.

This is your opportunity to join a highly focused forum of **70+ group** of oligo experts from **big pharma** and **innovative**, **leading**, **biotech** to share data, hard-earned lessons, and forward-looking strategies to accelerate development. Over three days, you will gain practical insights into refining oligonucleotide design for **enhanced stability** and **precision**, **advancing delivery platforms** from **conjugates** to **nanoparticle systems**, **integrating oligonucleotides** into **combination strategies**, and spotlighting how emerging tools are reshaping how oligo therapeutics are discovered and optimized.

If you are working to push oligonucleotide therapeutics into their next phase of growth, the 2nd Oligonucleotide-Based Therapeutics Summit is your unique opportunity to cut through the noise, get straight into the detail, and make connections that last beyond the conference by being part of the conversation that defines how oligos will deliver their full therapeutic potential.

What This Years Speakers Have to Say

"Oligonucleotides represent a transformative class of precision medicines that offers new treatment options for previous undruggable targets. I am excited to speak at the 2nd Oligo-based Therapeutics Summit where experts from chemistry, delivery science and biology unite to advance this rising therapeutic."

Biogen

Key Benefits of Attending

Gain a comparative view of what's actually working in extrahepatic delivery, benchmarking blood-brain barrier engineering and the transferrin receptor debate against AI-engineered miniproteins and ligand discovery beyond GalNAc and TfR, direct from **Harvard Wyss Institute**, **UMass Chan Medical School**, **Cellado Bio**, **Vivatides Therapeutics**, and **Evercrisp**. Accelerate your own R&D strategy by learning from real-world successes and challenges, and leave with actionable insights that can help de-risk and advance your oligonucleotide programs faster.

Leave with a practical framework for ligand selection, linker design, and navigating CMC/ manufacturability trade-offs, built through a dedicated interactive workshop with **City Therapeutics**, **Cellado Bio** and **Judo Bio**, to improve selection of the right ligand-target combination for extrahepatic delivery and optimize linker design to balance delivery efficiency, and stability.

Stay ahead of the next wave of oligonucleotide design and mechanism innovation by forming your own informed view on the chemistry innovations dividing the field, circular ASOs, RNA 2'-OH covalent modification, and oligonucleotides that upregulate gene expression, by watching a live "hot seat" cross-examination of whether saRNA is a genuine breakthrough or unproven promise, with **Korro Bio**, **CAMP4 Therapeutics** and **Prime Medicine**, helping you make more informed platform investment and R&D prioritization decisions.

Understand why biodistribution does not always correlate with therapeutic activity, oligonucleotide accumulation in tissue does not always translate to function, and get a working grasp of the field's rate-limiting step, confronting endosomal escape and the depot effect head-on, with perspectives from **UCSD**, **UMass Chan Medical School** and **NanoDe Therapeutics**, ultimately strengthening the translational potential of your therapeutic program.

Get a candid, insider read on exactly what makes an oligonucleotide programme stand out for partnership, in-licensing, or acquisition, straight from **D2B3** and fellow external innovation leaders in an open panel conversation, a direct opportunity to build meaningful relationships with peers, collaborators, and potential partners who are actively evaluating deals in this space.

+1 617 455 4188 info@hansonwade.com
www.oligonucleotide-based-therapeutics.com

hansonwade

What's New For 2026?

2nd Annual Oligonucleotide-based Therapeutics Summit
December, 8-10, 2026 | Boston, MA

Dedicated Pre-Conference Workshop Day

Attendees can explore a case study-led comparison of transferrin receptor conjugates, antibody shuttles, ligand-based targeting and non-conjugated approaches, leaving with a practical framework to evaluate the risks associated with each delivery strategy in their own programs.

A second workshop will examine the next generation of conjugates, ligands and linkers, providing focused insights into ligand discovery, linker design, and the CMC and manufacturability trade-offs involved in developing more effective and scalable delivery systems.

Paul Peng
City Therapeutics

Alfica Sehgal
Judo Therapeutics

Jacek Ostrowski
Avidity Bioscience

Ken Yamada
UMass Chan Medical School

New Session Formats

2026 introduces two new interactive formats: the **Innovation Lab**, where small groups work through real receptor and linker chemistry challenges live, and the **Hot Seat**, where a single divisive technology faces direct, moderator-led cross-examination in front of the room. Both are built for topics the field is still genuinely split on, saRNA, endosomal escape, and receptor/linker design, where a straight presentation wouldn't cut it.

Screening Beyond GalNAc and TfR & Identifying Which Novel Targeting Ligands Are Actually Worth Pursuing

Cecilia Leung
Vivatides Therapeutics

Move beyond established receptors and discover how target-agnostic ligand discovery platforms, including mRNA display, DNA-encoded libraries and AI or ML-driven optimization, are helping teams identify the most promising next-generation targeting ligands. Delegates will gain insight into how to better evaluate novel ligand opportunities before committing time and resources.

AI-Engineered Miniproteins for Targeted Oligonucleotide Delivery

Stephanie Maiocco
Evercrisp

A new delivery modality for 2026, AI-designed miniproteins enabling receptor-mediated siRNA uptake in muscle

Confronting Endosomal Escape & the Depot Effect: Understanding Why Accumulation Doesn't Always Mean Activity

Explore one of the biggest barriers in oligonucleotide delivery: why tissue accumulation does not always lead to effective gene silencing. With dedicated sessions on endosomal escape and the depot effect, delegates will gain a clearer understanding of the mechanisms limiting functional delivery and how to more accurately assess true therapeutic activity.

Steven Dowdy
UCSD Medical School

Qian Chen
NanoDe Therapeutics

Ken Yamada
UMass Chan Medical School

13 New Companies for 2026! Here Are 6 of Them:

City Therapeutics	judobio	Cellado Inc.	VIVATIDES THERAPEUTICS	KORRO BIO	prime medicine
Bringing CMC and ADC-style engineering perspectives to conjugate delivery design	Adding ligand and linker optimization expertise to the conjugates workshop	Sharing engineering design principles for extrahepatic oligonucleotide delivery	Introducing target-agnostic ligand discovery platforms beyond GalNAc and TfR	Presenting novel RNA 2'-OH covalent modification chemistry	Debating the maturity of saRNA in the live hot seat session

+1 617 455 4188 info@hansonwade.com
www.oligonucleotide-based-therapeutics.com

hansonwade

Your Expert Speakers

Next-Generation Biotech & Innovative Pharma

Sudhir Agrawal
President
ARNAY Sciences

Jacek Ostrowski
Senior Director, Protein Science
Avidity Bioscience

Jiabao Zhang
Senior Scientist
Biogen

Daniel Tardiff
Chief Scientific Officer
CAMP4 Therapeutics

Seymour de Picciotto
Chief Executive Officer
Cellado Bio

Paul Peng
Vice President, Head of CMC
City Therapeutics

Manuel Mohr
Chief Executive Officer
D2B3

Stephanie Maiocco
Vice President of Biotherapeutics
Evercrisp

Shuhan Huang
Scientist
Harvard WYSS Institute

Alfica Sehgal
Chief Scientific Officer
Judo Therapeutics

Sayantan Chatterjee
Scientist, Oligonucleotide Chemistry
Korro Bio

Qian Chen
Scientific Founder
NanoDe Therapeutics

Rowshon Alam
Head Vice President, Chemistry
Prime Medicine

Cecilia Leung
Vice President of Research
Vivatides Therapeutics

Pioneering Academia

Steven Dowdy
Professor
UCSD Medical School

Ken Yamada
Assistant Professor, RNA Therapeutics Institute
UMass Chan Medical School

Julia Alterman
Assistant Professor
UMass Chan Medical School

Thomas Orsby
Postdoctoral Associate
UMass Chan Medical School

Pre-Conference | Workshop Day
Tuesday, December 8th

Check-In & Coffee 8.00

Workshop A 9.00

Comparing Today's Leading Extrahepatic Delivery Strategies & Building a Practical Framework for Your Own Program to Accelerate Clinical Translation

Interactive, case study-led workshop exploring how leading developers are overcoming the biological barriers limiting oligonucleotide delivery beyond the liver. Through real-world development examples and collaborative discussion, attendees will evaluate the trade-offs between emerging targeting platforms and leave with a practical framework for selecting the right delivery strategy for their own programmes.

Workshop highlights

- Work through real-world case studies of extrahepatic and CNS delivery programmes to understand where promising approaches translated successfully and where they broke down between preclinical models and the clinic
- Compare transferrin receptor conjugates, antibody shuttles, ligand-based targeting and non-conjugated approaches to determine which strategy is best suited to different tissues, indications and therapeutic modalities
- Leave with a practical framework to identify whether delivery strategy, targeting ligand or oligonucleotide chemistry represents the greatest development risk in your programme and where to focus optimisation efforts first

Workshop Leaders

Ken Yamada
Assistant Professor, RNA Therapeutics Institute
UMass Chan Medical School

Jacek Ostrowski
Senior Director, Protein Science
Avidity Bioscience

Lunch Break & Networking 12.00

Workshop B 1.00

Building the Next Generation of Conjugates, Ligands & Linkers for Targeted Oligonucleotide Delivery to Unlock Extrahepatic Tissues & Improve Therapeutic Efficacy

Interactive workshop exploring how developers are designing, selecting and optimizing conjugates, ligands and linkers to improve tissue-specific delivery and maximize therapeutic performance. Through expert discussion and practical case studies, attendees will evaluate the critical design decisions that influence target efficiency, manufacturability, safety and long-term platform potential.

Workshop highlights

- Evaluate the latest ligand discovery strategies, comparing established targets such as ASGPR and transferrin receptor with emerging receptor biology to identify new opportunities for tissue-specific delivery
- Explore how linker design influences conjugate performance, understanding the impact of stability, release mechanisms and pharmacokinetics on efficacy, safety and therapeutic index
- Understand the CMC and manufacturing considerations that shape successful conjugate development, including process scalability, raw material selection, technology transfer and the impact of design decisions on manufacturability and clinical supply
- Leave with a practical framework for building a competitive targeting platform, including the key scientific, translational and commercial questions partners and investors will expect your technology to answer before advancing into collaboration or development

Workshop Leaders

Paul Peng
Vice President, Head of CMC
City Therapeutics

Alfica Sehgal
Chief Scientific Officer
Judo Therapeutics

End of Workshop Day 4.00

Conference Day One
Wednesday, December 9th

7.30 **Check-In & Coffee**

Jacek Ostrowski
Senior Director, Protein Science
Avidity Bioscience

8.50 **Chair's Opening Remarks**

Paul Peng
Vice President, Head of CMC
City Therapeutics

9.00 **Industry Leader's Fireside Chat: Tracing Antibody Engineering's Evolution Into ADC-Style Oligo Delivery & Charting Where the Field Is Headed Next**

Exploring how priorities have shifted across the ecosystem, from proving modality feasibility to solving delivery, scalability and commercialization challenges, and what this means for the next generation of RNA therapeutics.

- Gain insight into the evolving innovation landscape, including how changing investment priorities, strategic collaborations and platform consolidation are influencing the future direction of oligonucleotide therapeutics and partnership opportunities
- Delving into the scientific, manufacturing and strategic considerations that determine whether innovative delivery technologies successfully translate from platform concepts into approved medicines

Shuhan Huang
Scientist
Harvard WYSS Institute

9.30 **What It Takes to Build the Next Generation of Blood-Brain Barrier Therapies**

- Gain first-hand insights into the scientific and translational advances that are redefining blood-brain barrier delivery and creating new opportunities for oligonucleotide therapeutics beyond the liver
- Explore where meaningful progress has been made in extrahepatic and CNS delivery over the past two years, distinguishing genuine breakthroughs from the challenges that continue to limit clinical translation
- Set the strategic context for the summit by understanding the opportunities, bottlenecks and innovation priorities that will shape the future of oligonucleotide delivery

10.00 **Morning Break & Speed Networking**
As this community unites, this session will provide valuable networking time with your peers, enabling you to forge new and lasting connections.

Breaking Through Delivery Barriers Beyond the Liver to Expand Therapeutic Opportunities

Seymour de Picciotto
Chief Executive Officer
Cellado Bio

11.00 **Analyzing Emerging Strategies & Future Design Principles for Engineering Extrahepatic Oligonucleotide Delivery**

- Analyzing engineering principles underpinning successful extrahepatic oligonucleotide delivery and how different approaches overcome tissue-specific barriers
- Drawing practical lessons from recent publications to identify common themes and emerging best practices
- Compare the strengths and limitations of conjugated and non-conjugated approaches to identify which strategy is best suited to different disease indications and development goals

Julia Alterman
Assistant Professor
UMass Chan Medical School

11.30 **Advancing Precision RNAi for Fibrodysplasia Ossificans Progressiva Through a Combinatorial, Unimolecular, Allele-Selective Approach**

- Combining a SNP-specific siRNA with an inflammatory target to tackle both the underlying genetic driver and disease progression in fibrodysplasia ossificans progressiva
- Developing multimeric oligonucleotide architectures to simultaneously address multiple disease-driving pathways
- Demonstrating therapeutic potential through both preventative and therapeutic models, including local and systemic delivery

Conference Day One
Wednesday, December 9th

Thomas Orsby
Postdoctoral Associate
UMass Chan Medical School

12.00 **Enabling Targeted Muscle Delivery Through Aptamer-siRNA Conjugates Beyond Antibody Conjugates**

- Repurposing transferrin receptor 1 (TfR1)-binding aptamers as targeting ligands for systemic siRNA delivery
- Achieves selective and durable siRNA activity in skeletal muscle following a single systemic dose
- Establishes aptamer–siRNA conjugates as a promising platform for next-generation targeted oligonucleotide therapeutics

12.30 **Lunch Break & Networking**

Thomas Orsby
Postdoctoral Associate
UMass Chan Medical School

1.30 **Roundtable Discussion: Is Transferrin Receptor Targeting Still the Future of Delivery?**

An interactive panel discussion bringing together experts developing next-generation delivery technologies to debate the future of transferrin receptor targeting, emerging alternatives and the scientific challenges that remain in achieving effective delivery

- Compare the strengths and limitations of IgG, Fab, VHH and bispecific transferrin receptor targeting strategies to understand where each approach is demonstrating the greatest translational potential
- Debate whether continued optimisation of transferrin receptor biology is enough or if the field must identify new receptors and targeting mechanisms to unlock the next generation of oligonucleotide-based therapeutics
- Put your questions directly to the panel and gain practical insights into the opportunities, remaining barriers and future direction of transferrin receptor delivery

Expanding the Delivery Toolbox Through Novel Ligands, Receptor Targeting and Bioconjugation Strategies

Cecilia Leung
Vice President of Research
Vivatides Therapeutics

2.15 **Screening Beyond GalNAc and TFR & Identifying Which Novel Targeting Ligands Are Actually Worth Pursuing**

- Explore how target-agnostic ligand discovery platforms, including mRNA display and DNA-encoded libraries, are uncovering previously unexplored receptor targets for selective oligonucleotide delivery
- Understand how AI and machine learning approaches applied to real screening datasets are being used to optimise ligand properties, improve binding characteristics and enhance delivery performance
- Gain practical insights into how emerging ligand discovery technologies can be integrated into your own oligonucleotide development programmes to expand targeting opportunities beyond current approaches

Stephanie Maiocco
Vice President of Biotherapeutics
Evercrisp

2.45 **AI-Engineered Miniproteins for Targeted Oligonucleotide Delivery: Enabling Receptor-Mediated Uptake Beyond the Liver**

- Showcase the application of AI-designed miniproteins for siRNA delivery to muscle, including evidence of functional target knockdown
- Examine the key challenges in translating receptor binding and cellular uptake into effective intracellular delivery and pharmacology
- Consider how targeted miniprotein delivery could expand the reach of oligonucleotide therapeutics to tissues and cell types that remain difficult to access

3.15 **Afternoon Break & Poster Session**
This is your opportunity to contribute to the conversation and share your cutting-edge research with this community while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.

Conference Day One
Wednesday, December 9th

4.15 **Innovation Lab: Novel Receptors & Linker Chemistry: Unlocking the Next Frontier in Targeted Oligonucleotide Delivery**

Sayantan Chatterjee
Scientist, Oligonucleotide Chemsitry
Korro Bio

Brand New Interactive Session

The next generation of oligonucleotide therapeutics will require more than incremental improvements to existing delivery approaches. This interactive innovation lab will bring together researchers to explore emerging receptor targets, linker design strategies and the critical chemistry challenges that influence delivery performance, stability and therapeutic potential

- Bring your own receptor targeting or linker chemistry challenges to the discussion and gain practical insights from peers working through similar delivery bottlenecks
- Explore how linker design impacts conjugate stability, tissue distribution, cellular uptake and intracellular release
- Discuss emerging opportunities in novel receptor targeting and how underexplored delivery mechanisms could expand the reach of oligonucleotide therapeutics
- Leave with new perspectives, potential solutions and valuable connections to advance your own delivery programs

Jacek Ostrowski
Senior Director, Protein Science
Avidity Bioscience

5.00 **Chair's Closing Remarks**

5.15 **End of Conference Day One**

> "I enjoyed the highly relevant technical presentations and the opportunity to exchange ideas with experts across the oligonucleotide field. What stood out most was the practical insights into analytical development, CMC challenges, and emerging industry technologies"
>
> **Alnylam Pharmaceuticals**

Conference Day Two
Thursday, December 10th

8.00 Check-In & Coffee

Jacek Ostrowski
Senior Director,
Protein Science
Avidity Bioscience

8.50 **Chair's Opening Remarks**

Engineering the Future of Oligonucleotides with New Chemistries, Designs & Therapeutic Opportunities

Sudhir Agrawal
President
ARNAY Sciences

9.00 **Circular ASOs: Exploring Chemistry Behind the Next Wave of Antisense Innovation**

- Explore the chemistry behind circularised antisense oligonucleotides and understand how these designs differ from conventional linear gapmer ASOs
- Evaluate whether circularisation can meaningfully improve stability, pharmacokinetics and therapeutic durability compared with existing antisense approaches
- Gain deeper technical insight into an emerging chemistry platform that has rapidly gained industry attention but remains relatively unexplored from a development perspective

Sayantan Chatterjee
Scientist,
Oligonucleotide
Chemistry
Korro Bio

9.30 **Advancements in RNA 2'-OH Covalent Modification with Reactive Small Molecules**

- Introduce RNA 2'-OH modification as a versatile post-synthetic conjugation strategy for oligonucleotides that can go beyond what is possible with standard solid-phase oligonucleotide synthesis
- Describe the chemical classes that can drive these reactions, their advantages/ disadvantages, and how they may be manufactured
- Applications of this technology to oligonucleotide stability enhancement, delivery, and structure analysis, and where future work may lead to effective drug development

10.00 Morning Break & Networking

Daniel Tardif
Chief Scientific Officer
CAMP4 Therapeutics

11.00 **Targeting Noncoding Regulatory RNAs for the Potential Treatment of Human Disease**

- Explore the rationale and approach for targeting non-coding RNAs to upregulate gene expression for diverse therapeutic applications
- Discuss how the platform enables discovery of antisense oligonucleotides that can increase transcription across a range of therapeutic indications and target tissues.
- Provide case studies on the translation and development of candidate ASOs from preclinical research to the clinic

Jiabao Zhang
Senior Scientist
Biogen

11.30 **From Novel ASO Chemistry to Scalable Manufacturing: Overcoming Emerging Process & Safety Challenges**

- Introducing a novel and highly potent ASO modification and the manufacturing considerations associated with its development
- Discussing how process parameters can be optimised to maintain product quality while enabling safe and robust manufacturing
- Exploring how teams can identify and address unexpected chemistry and process bottlenecks during development

Conference Day Two
Thursday, December 10th

12.00 **Interactive Hot Seat: saRNA Breakthrough or Unproven Promise? A Live Scientific Debate**

Rowshon Alam
Head Vice President, Chemistry
Prime Medicine

Sudhir Agrawal
President
ARNAY Sciences

Brand New Interactive Session

Small activating RNA remains one of the most debated areas within RNA therapeutics, with supporters highlighting its potential for durable gene activation whilst critics question its maturity, scalability and clinical translation. This live hot seat will challenge assumptions around saRNA development, bringing opposing perspectives together to examine where science stands today and what needs to happen for broader adoption

- Watch a controversial and evolving technology be critically examined through a live cross-examination rather than a traditional presentation format
- Explore the key scientific and development questions around saRNA, including delivery, durability, specificity and clinical readiness
- Gain a balanced perspective on whether saRNA represents a future therapeutic opportunity or remains an area requiring further validation before significant investment

12.45 **Lunch Break & Networking**

Confronting Endosomal Escape and the Depot Effect & Understanding Why Accumulation Doesn't Always Mean Activity

1.45 **Interrogating the Depot Effect & Accumulation of siRNAs & ASOs to Improve Safety, Enable Sustained Release & Extend Dosing Intervals**

Qian Chen
Scientific Founder
NanoDe Therapeutics

- Understand why certain tissues can accumulate high levels of siRNA and ASOs while showing limited or no measurable gene silencing activity
- Explore how to distinguish productive versus unproductive intracellular trafficking pathways and identify the factors that determine functional delivery
- Examine emerging approaches to rescue oligonucleotides trapped in non-productive pathways, including dual-receptor strategies and next-generation delivery innovations

2.15 **Chemical Engineering of siRNA toward Modulating Endosomal Escape Kinetics**

Ken Yamada
Assistant Professor, RNA Therapeutics Institute
UMass Chan Medical School

- Poly-dxC (exNA-dC) self-assembles into iMotif structures (ex-iM) specifically under the acidic pH condition
- Poly-dxC-modified siRNA self-assembles within the cell in vitro, enhancing the kinetics of siRNA activity without inducing toxic endosomal membrane rupture
- Poly-dxC-modified siRNA improves gene-silencing kinetics in vivo, with substantially enhanced early-time-point silencing in mouse kidney

2.45 **Endosomal Escape The Field's Rate-Limiting Step in Unlocking Oligonucleotide Potency**

Steven Dowdy
Professor
UCSD Medical School

- Gain insights from a leading researcher in endosomal escape on why overcoming this barrier remains a central challenge for the next generation of oligonucleotide therapeutics
- Understand the mechanistic gap between cellular uptake and functional cytosolic delivery, including why many internalised oligonucleotides fail to reach their intended site of action
- Evaluate emerging endosomal escape strategies and distinguish approaches showing genuine promise from those that remain early-stage or speculative

3.15 **Afternoon Break & Networking**

Conference Day Two
Thursday, December 10th

Manuel Mohr
Chief Executive Officer
D2B3

4.15 **Roundtable Discussion: What Are You Actually Looking For? An Open Conversation with Pharma BD and External Innovation Leaders**

Understanding what drives successful partnerships is critical for emerging oligonucleotide companies looking to secure investment, collaboration or acquisition opportunities. This candid panel will bring together pharma business development, external innovation and investment leaders to discuss what truly differentiates programs that attract strategic interest, from scientific validation and platform maturity to team capabilities and commercial potential.

- Hear directly from pharma BD and external innovation leaders on the scientific, technical and strategic signals that make an oligonucleotide programme stand out as a partnership opportunity
- Gain insight into how companies should position emerging platforms, technologies and assets to align with evolving pharma priorities and investment strategies
- Ask your questions directly and understand what decision-makers are evaluating when considering partnerships, collaborations and future opportunities

Jacek Ostrowski
Senior Director,
Protein Science
Avidity Bioscience

5.00 **Chair's Closing Remarks**

5.15 **End of Conference**

"The experience was thoroughly enjoyable due to the great networking opportunities and the relevance of the topics discussed. The smaller setting allowed for more meaningful conversations and easier access to speakers and fellow attendees."

Alnylam Pharmaceuticals

Our Partners

Exhibition Partner

Ajinomoto Bio-Pharma Services is a global CDMO with sites in Belgium, India, the US, and Japan. They provide comprehensive one-stop services from process development to GMP manufacturing of pharmaceutical ingredients and intermediates for small, medium, and large molecules, as well as gene therapy. Their capabilities span pre-clinical to commercial stages, supported by proprietary platforms: AJIPHASE® (liquid-phase oligo/peptide), CORYNEX® (microbial protein/peptide expression), AJICAP® (site-specific conjugation for drug conjugates), and Fuel (AAV gene therapy).

www.ajibio-pharma.ajinomoto.com

Get Involved

Tazeen Kapadia
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partnership Opportunities

2nd Annual Oligonucleotide-based Therapeutics Summit
December, 8-10, 2026 | Boston, MA

Your Global Platform to Foster New & Existing Relationships within the Rapidly Evolving Oligonucleotide Therapeutics Space

As one of the **only meetings dedicated exclusively to advancing oligonucleotide chemistry and delivery beyond the liver**, this summit provides a unique platform for industry leaders to engage directly with the scientists and decision-makers driving the field's next wave of innovation. With an intimate audience of **70+ senior experts** from across biopharma and biotech, this is your opportunity to move beyond surface-level conversations and build the relationships that matter.

Raise Your Brand Awareness

Position your company in front of a highly targeted audience of scientists and decision-makers actively working to solve oligonucleotide delivery, chemistry and manufacturability challenges, ensuring your brand is front of mind when programs look for the right partners to move forward.

Distinguish Yourself from the Crowd

Unlike larger, broader RNA therapeutics meetings that cover the entire oligonucleotide landscape, this summit's focused agenda gives partners the space to demonstrate deep technical expertise in extrahepatic delivery, conjugate design and next-generation chemistry, rather than competing for attention across a crowded, generalist program.

Generate Commercial Opportunities

With dedicated content exploring what pharma business development and external innovation leaders are looking for in a partnership, this summit puts you directly in the room with the teams evaluating in-licensing, collaboration, and investment opportunities in oligonucleotide therapeutics.

Is Your Company One of These Solutions Drug Developers Are Looking For?

Every session on this agenda was built from direct conversations with the scientists and technical leaders in the room, which means we know exactly what they're currently struggling to solve. If your company sits in one of the verticals below, this is where your buyers already are:

- **Delivery Platforms & Targeting Technologies**, transferrin receptor shuttles, non-conjugate delivery chemistry, novel ligand and receptor discovery, miniprotein and bioconjugation platforms
- **Linker & Conjugation Chemistry**, a technology area our own research flagged as consistently underexplored, precisely because most biotech and pharma teams don't have the internal bandwidth to solve it themselves
- **Preclinical & In Vivo Testing / CRO Services**, biodistribution, PK/PD, and translational testing for extrahepatic and CNS delivery programs, including the mouse-to-NHP gap that repeatedly comes up as the field's most common point of failure
- **Analytical Characterization**, diastereomer profiling, potency assays, and identity testing, especially for the antibody-oligonucleotide conjugates that standard QC environments aren't always equipped for
- **AI / ML-Driven Design & Discovery**, computational ligand optimization, target-agnostic screening, and de-risking frameworks applied to real (not simulated) data
- **Chemistry & Synthesis Innovation**, enzymatic synthesis, novel backbone chemistries, and platforms addressing the stability-safety trade-off in molecular design
- **Manufacturing & Scale-Up**, CDMO and process technology partners helping translate promising chemistry into fundable, scalable programs

If your solution fits one of these categories, we'd encourage you to identify it directly in your sponsorship enquiry, it helps us make sure you're placed in front of the right conversations on the agenda, not just the right room.

Seniority of Attendees



- Director 33%
- Scientist / Researcher 18%
- C-Level / Founder 14%
- VP / SVP 15%
- Manager 12%
- Other 8%

Type of Companies Attending



- Pharma / Biotech
- Service Provider
- Investment / Venture
- Other

Statistics Taken from the 1st Oligonucleotide-based Therapeutics Summit

Get Involved



Tazeen Kapadia
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.oligonucleotide-based-therapeutics.com/take-part/register/

Tel: US +1 617 455 4188 /
EU +44 (0)20 3141 8700

Email: info@hansonwade.com

DISCOVER how leading biopharma and biotech companies are engineering smarter oligonucleotide chemistry and next-generation delivery strategies to overcome the field's most pressing barrier, reaching beyond the liver into CNS, muscle, and other hard-to-access tissues.

BUILD your understanding of the current challenges, strategies and solutions shaping extrahepatic delivery, conjugate design, and endosomal escape, from practical case studies and live scientific debate to hands-on workshops you can apply directly to your own program.

ENGAGE with your community and peers from across pharma, biotech and academia to build lasting connections, uncover complementary collaborations, and help shape the future of oligonucleotide therapeutics.

Drug Developers	Register & Pay By Friday, Sep 18	On the Door Price
Conference + Workshop Day	$3,397 **(Save $1000)**	$4,397
Conference Only	$2,599 **(Save $500)**	$3,099

Academic & Research Institutes**	Register & Pay By Friday, Sep 18	On the Door Price
Conference + Workshop Day	$2,797 **(Save $1000)**	$3,797
Conference Only	$2,199 **(Save $500)**	$2,699

Solution & Service Providers	Register & Pay By Friday, Sep 18	On the Door Price
Conference + Workshop Day	$4,297 **(Save $1000)**	$5,297
Conference Only	$3,299 **(Save $500)**	$3,799

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Aloft Boston Seaport District
401-403 D Street, Boston, Massachusetts, USA, 02210
www.marriott.com/en-us/hotels/bosal-aloft-boston-seaport-district/overview/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom